FN14 Signaling Plays a Pathogenic Role in a Mouse Model of Experimental Autoimmune Myocarditis |
| |
Authors: | ANDREA Fischer MARIELLA BOCKSTAHLER ANNA-MARIA MÜLLER VERA STROIKOVA CHRISTOPH LEIB GABRIELE PFITZER HUGO A. KATUS ZIYA KAYA |
| |
Affiliation: | 1. Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany;2. Cardiology, St. Claraspital, 4058 Basel, Switzerland;3. Institute of Vegetative Physiology, University of Cologne, 50931 Cologne, Germany;4. DZHK (German Centre for Cardiovascular Research), partner site Heidelberg/Mannheim, University of Heidelberg, 69120 Heidelberg, Germany |
| |
Abstract: | BackgroundThe pathogenesis of inflammatory cardiomyopathy is affected by the activation of autoimmune-mediated cascades. To study these cascades, we developed an experimental model of troponin I (TnI)-induced autoimmune myocarditis (EAM). One factor playing a pivotal role in the context of autoimmune disorders is the receptor fibroblast growth factor-inducible 14 (FN14). Thus, the impact of FN14 in the development of autoimmune myocarditis was investigated.Methods and ResultsTnI-immunization led to a significantly increased myocardial FN14 mRNA and protein expression in wild-type (wt) mice. To investigate the precise role of FN14 in EAM, FN14 knockout (ko) and wt littermates were immunized with TnI or control buffer. The animals were evaluated for cardiac parameters and indicators of myocardial injury. FN14 deficiency resulted in better cardiac performance, less myocardial inflammation, fibrosis, and cardiac damage. A lower myocardial mRNA expression of inflammatory cytokines and chemokines as well as their receptors could be demonstrated in TnI-immunized FN14ko compared to wt mice also immunized with TnI. Western blot analysis revealed a contribution of nuclear factor kappa-light-chain-enhancer of activated B cells to FN14-induced signaling cascades.ConclusionsIn the pathogenesis of autoimmune myocarditis, the inflammatory response to cardiac injury is attenuated in FN14ko mice. Thus, inhibition of FN14 in patients might represent a novel therapeutic strategy in the treatment of inflammatory cardiomyopathy. |
| |
Keywords: | Reprint requests: Ziya Kaya, Department of Cardiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Tel.: +49 6221 5639617 Fax: +49 6221 565516. Inflammation cytokines heart failure Nfκb |
本文献已被 ScienceDirect 等数据库收录! |
|